Peripheral blood smear from a patient with suspected chronic lymphocytic leukemia (CLL) shows a predominance of small, mature-appearing lymphocytes with scant cytoplasm and clumped nuclear chromatin, accompanied by fragile cells that readily disrupt during smear preparation, producing numerous smudge or basket cells visible on the slide. The image depicts a single smudge cell in the upper right, with numerous small darkly staining lymphocytes occupying the field. The smear was prepared with Wright-Giemsa stain and examined under light microscopy at high magnification (approximately 1000x total magnification with oil immersion). Clinically, CLL is defined by absolute mature lymphocytosis of ≥5.0 × 10^9/L sustained for ≥3 months, often asymptomatic and detected incidentally on complete blood count. Morphology alone is insufficient for diagnosis; immunophenotyping showing co-expression of CD5, CD19, CD23 with weak surface immunoglobulin and light chain restriction supports CLL diagnosis. Smudge cells result from fragile leukemic cells and reflect underlying cytoskeletal fragility, though they are not specific. The image illustrates typical features: monomorphic lymphocytes, scant cytoplasm, condensed chromatin, and absent prominent nucleoli. This finding has diagnostic significance, guiding further workup, including flow cytometry, cytogenetics, and molecular studies, to distinguish CLL from other chronic lymphoproliferative disorders such as small lymphocytic lymphoma (SLL), mantle cell lymphoma, prolymphocytic leukemia, and reactive lymphocytosis.

This image depicts a peripheral blood smear prepared with Wright-Giemsa stain and examined under light microscopy at high magnification. The predominant features are small, mature-appearing lymphocytes with scant cytoplasm and discrete basophilic nuclei interspersed among erythrocytes. A characteristic subset of circulating lymphocytes displays short, polarity-restricted cytoplasmic villi (finger-like projections) consistent with splenic marginal zone lymphoma (SMZL) involvement of peripheral blood. The villi are typically slender and localized to one pole of the cell, unlike the longer, circumferential villous extensions seen in hairy cell leukemia, which aids in differential diagnosis. Some lymphocytes appear slightly irregular or irregular nuclear contours; occasional larger atypical cells may be present but are less common. The background shows normocytic red cells with normal distribution; platelets are not prominent. This cytomorphology supports SMZL in the context of known splenomegaly or lymphoproliferative disease and is often corroborated by immunophenotyping and molecular studies. Clinically, peripheral blood involvement occurs in roughly half to two-thirds of SMZL cases and helps establish disease burden. The image illustrates the diagnostic utility of meticulous peripheral smear review for small-vessel lymphocytosis and villous lymphocytes, informing differential diagnoses, guiding flow cytometry panels, and contributing to monitoring and prognosis.

Peripheral blood smear prepared from a patient with suspected plasma cell leukemia (PCL) was examined by bright‑field light microscopy after Wright‑Giemsa staining. The smear shows several circulating plasma‑cell–like elements, including four conspicuous proplasmacytes with dispersed nuclear chromatin and prominent nucleoli, as indicated by arrows in the original figure. In addition, background erythrocytes exhibit rouleaux formation, a common feature in paraproteinemic states. The cells display eccentrically placed nuclei with pronounced basophilic cytoplasm and a coarse chromatin pattern; occasional cells show a perinuclear clearing (Golgi rim) suggestive of plasmacytic differentiation. Immunoglobulin light‑chain restriction is not determined on this smear alone but flow cytometry or immunohistochemistry would typically confirm clonal plasma cells. Relative proportions indicate that neoplastic plasma cells constitute a substantial fraction of leukocytes, consistent with plasma cell leukemia rather than reactive plasmacytosis. PCL is an aggressive myelomatous process often presenting with cytopenias, organomegaly, and sometimes lymphadenopathy; prognosis is poor, and treatment responsiveness is limited. This image illustrates characteristic morphologic features used for differential diagnosis against multiple myeloma, Waldenström macroglobulinemia, and other causes of plasmacytosis. Clinically relevant keywords include plasma cells, rouleaux, Wright‑Giemsa stain, 100X oil, peripheral blood, leukemia, myeloma, and hematologic malignancy.

This is a peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination at high magnification (approximately 1000x total, 100x objective with oil immersion). The smear displays predominantly erythrocytes with uniform pink cytoplasm and characteristic biconcave morphology, arranged singly with occasional rouleaux. Interspersed among the red cells are leukocytes with visible nuclei. Notably, two large lymphocyte-like cells or mononuclear leukocytes appear conspicuously larger than surrounding erythrocytes; these cells have round to oval, deeply basophilic nuclei with dense chromatin and scant, lightly basophilic cytoplasm. No visible granulocytic cytoplasm granules or multiple lobes are clearly resolved in this field, and there are no obvious nucleoli or cytoplasmic inclusions evident in these cells. The background lacks abnormal pigment or reticulocytosis. Overall cell morphology is consistent with a normal or mildly reactive hematologic smear; in a clinical context, additional data such as complete blood count, differential, and patient history would be needed to determine whether there is leukocytosis or blasts. This image serves as an educational reference for recognizing basic peripheral blood components, evaluating leukocyte size variation, and assessing RBC morphology for hematology training and diagnostic differential diagnoses. Additional cases and image contexts can reinforce recognition of hematologic normal variants and patterns.

A comparative medical illustration detailing therapeutic pathways for Chronic Myeloid Leukemia (CML) within the bone marrow niche. The diagram contrasts conventional Tyrosine Kinase Inhibitor (TKI) therapy with Anti-BCR/ABL gene therapy. The top pathway illustrates 'Leukemic Hematopoiesis': following TKI therapy, a mixed population of yellow Hematopoietic Stem Cells (HSCs), light blue TKI-sensitive Leukemic Stem Cells (LSCs), and dark blue TKI-resistant LSCs is shown. Treatment cessation or resistance leads to relapse, characterized by the proliferation of myeloid/lymphoid CML cells. The lower pathway depicts the potential of gene therapy: 'Anti-BCR/ABL gene therapy' targets LSCs to silence the oncogene (BCR/ABL OFF). This results in 'Corrected LSCs' (depicted with yellow and blue stripes), which repopulate the niche alongside normal HSCs. The final outcome is 'Normal Hematopoiesis' and the eradication of CML, visualised by the presence of mature myeloid/lymphoid blood cells (orange). The diagram serves as an educational tool for hematology and oncology, emphasizing the limitations of protein-level inhibition versus genome-level editing in stem cell niches.

Bone marrow aspirate smear analyzed by light microscopy with high magnification reveals marrow involvement by chronic lymphocytic leukemia (CLL) cells. The predominant population consists of small, dark lymphocytes with scant cytoplasm and condensed, clumped nuclear chromatin, producing high nuclear-to-cytoplasmic ratios. Occasional larger forms and prolymphocytes may be present but are uncommon. A consistent finding is the relative scarcity of cytoplasm and uniform round to slightly irregular nuclei among the bulk of lymphoid cells. The smear may show scattered megakaryocytes, reflecting concurrent hematopoietic activity within the aspirate. Morphology mirrors circulating leukemic cells, consistent with systemic disease. Clinically, such marrow infiltration is associated with cytopenias and advanced disease stage, especially when diffuse, solid infiltration predominates in core biopsy patterns; these patterns correlate with adverse prognosis and with expression of prognostic markers such as ZAP-70. The image corresponds to a high-magnification field intended to document cellular detail rather than architectural marrow patterns. Diagnostic significance lies in confirming lymphoid marrow involvement by CLL, quantifying blast equivalents is not applicable, and differentiating from other small B-cell neoplasms relies on adjunct flow cytometry, cytogenetics, and immunophenotyping. This representation is typical for educational, diagnostic, and research contexts describing CLL marrow morphology.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

This composite diagnostic image displays a comparison chart of hematological cells from non-cancerous bone marrow aspirations, organized to show the maturation stages of the myeloid series. The visual consists of a grid with six columns, each representing a specific stage of development: Myeloblast (MB), Promyelocyte (PM), Myelocyte (M), Metamyelocyte (MM), Band (B), and Neutrophil (N). The cells are stained with Giemsa, revealing characteristic morphological changes in nuclear and cytoplasmic structure. Early stages (MB, PM) show large, round to oval nuclei with high nuclear-to-cytoplasmic (N:C) ratios and basophilic cytoplasm. As maturation progresses through the Myelocyte and Metamyelocyte stages, the nuclei become smaller and more indented. The Band (B) stage is characterized by an elongated, curved, non-segmented nucleus. The terminal stage, the Neutrophil (N), demonstrates distinct nuclear lobulation (typically 2-3 lobes) and increased cytoplasmic granularity. This image serves as an educational reference for identifying white blood cell precursors in the context of healthy hematopoiesis and chronic myelogenous leukemia (CML) classification.

This infographic presents a 27-dimensional viSNE (visual t-distributed Stochastic Neighbor Embedding) analysis of mass cytometry data from two Acute Myeloid Leukemia (AML) patients, labeled F001 and F003, visualizing clinical response over time. The primary visualization for each patient includes a combined viSNE map of all live cells from all time points. A black outline demarcates the 'Leukemic Blast Area,' highlighted in orange, representing the phenotypic space occupied by malignant cells. Patient F001 is labeled 'Remission,' while Patient F003 is labeled 'No Remission.' To the right, series of longitudinal viSNE maps represent specific time points (Day 0, 3, 5, 10, 14, and Recovery) from both bone marrow and peripheral blood. In these temporal maps, cells from the specific time point are highlighted in red against a grey background of all historical cells. The visualization demonstrates educational concepts in hematology-oncology, specifically the clearance of malignant blasts in the remission patient (F001) versus the persistence of the leukemic population within the blast area in the non-remission patient (F003) across induction therapy.

High-magnification brightfield micrograph of a human bone marrow aspirate smear stained with Hematoxylin and Eosin, demonstrating dysplastic megakaryocytes in a hematopoietic background. The megakaryocytes exhibit atypical nuclear morphology, including multinucleation, irregular lobulation, and nuclear fragmentation, with variable cytoplasmic basophilia. Background cellularity shows concurrent dyserythropoiesis and dysplastic myeloid precursors consistent with a myelodysplastic spectrum. Overall architecture may be hypercellular or variably cellular, with scattered normal hematopoietic elements interspersed among abnormal cells. Features are most prominent in the megakaryocytic lineage, where dysplasia is a salient hallmark. The image illustrates morphologic criteria that support a diagnosis in the context of possible progression toward acute leukemia, and should be correlated with peripheral blood counts, marrow blast percentage, cytogenetic and molecular studies. Clinically, such dysplastic megakaryocytes are associated with cytopenias and splenomegaly, and approximately a fifth of patients with related myelodysplastic/myeloproliferative conditions progress to acute myeloid leukemia. This representation is valuable for educational, diagnostic, and research purposes, particularly in studies of megakaryocytic dysplasia, MDS/AML continuum, prognostication, and therapeutic planning focused on palliation and cytopenia management. Careful documentation of features and context enhances reproducibility, supports standardized reporting, and facilitates cross-institutional data sharing for outcome studies and biomarker-driven clinical trials.

A composite clinical chart comprising three longitudinal line graphs (A, B, and C) tracking hematologic parameters in a patient over a multi-year period (2014–2020) during treatment for leukemia. Graph A (Blast Percent) displays a sharp, transient spike in peripheral blast percentage reaching approximately 70% in late 2014, followed by a rapid decline and sustained suppression near 0% through 2020, indicating successful induction of remission. Graph B (Platelet Trend) shows significant initial fluctuations in platelet count (range ~50–350 K/uL) before stabilizing within the normal to near-normal range (150–200 K/uL) following the initiation of combination therapy. Graph C (WBC Trend) illustrates a concurrent leukocytosis peak (~36 K/uL) coinciding with the blast crisis in late 2014, followed by stabilization within a normal range of 4–8 K/uL. These charts demonstrate the clinical efficacy of Vidaza (azacitidine) and Sorafenib in maintaining molecular and hematologic response in a patient with FLT3-mutated acute myeloid leukemia (AML).